Objective:

Establish NGS testing as part of the standard of care for all patients with onco-haematological conditions in the Middle East.

Challenges:

  • Limited access to NGS testing impedes optimal care delivery in the Middle East. The absence of NGS availability may result in under-diagnosis of specific conditions and mismanagement of others, critically impacting patient outcomes where accurate diagnosis and management are paramount.
  • The Middle East and Africa NGS market share is expected to reach 800million by 2029

Approach:

  • Establish accessible NGS facilities via UCL/HSL laboratories in London
  • Work with local partners, hospitals and health ministries to receive samples for testing
  • Integrate NGS testing into routine clinical practice.
  • Provide feedback to clinicians, critically analyzing NGS data and updating patient management strategies accordingly, including MRD (minimal residual disease) testing post-treatment.
  • Develop educational programs to raise awareness among healthcare professionals and patients.

Partnerships:

  • Collaborate with local stakeholders, including healthcare providers, academic institutions, and government agencies.
  • Partner with HSL Laboratories and University College London (UCL) for expertise in NGS technology and academic oversight, leveraging high-level expertise from UCL, one of the biggest Haematology centers in Europe.

Sustainability Plan:

  • Implement revenue-generating models, including charging per test
  • Increasing workload will reduce operational costs, making the technology more affordable
  • sponsorship schemes
  • Continuously evaluate and adapt based on stakeholder feedback and technological advancements.

Expected Impact:

Improved patient outcomes, access to state-of-the-art healthcare, training of local healthcare providers, and contribution to the global effort to combat cancer and blood disorders.